- Teva Pharmaceutical Industries is set to present data for various products, indicating ongoing research and potential for growth.
- Teva’s CEO sees ‘significant’ potential for a trio of branded drugs, which could drive future revenue and profits.
- Teva’s strategic evaluation, including the potential sale of its active ingredients unit, might create opportunities for restructuring and focus on core operations.
- Teva agreed to pay significant settlements, including $225 million to settle price-fixing charges and $126 million to US hospitals over opioids, which could impact its financials.
- The heavy institutional ownership of 55% might limit the company’s flexibility and decision-making.
- Challenges in the pharmaceutical industry, such as drug shortages and market competition, could affect Teva’s performance.
investment score = chances characters count - risks characters count
- 2023-09-07 Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
- 2023-09-06 Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023
- 2023-09-02 With 55% ownership of the shares, Teva Pharmaceutical Industries Limited (NYSE:TEVA) is heavily dominated by institutional owners
- 2023-09-01 Q2 2023 Alvotech SA Earnings Call
- 2023-08-31 Alkermes (ALKS) Grants Teva License to Market Generic Drug
- 2023-08-23 TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)
- 2023-08-22 TEVA to Pay $250 Million to Settle Price-Fixing Charges
- 2023-08-22 Teva Agrees to Pay $225 Million to Settle U.S. Price-Fixing Charges
- 2023-08-22 Teva to pay $225M to settle cholesterol drug price-fixing charges
- 2023-08-22 UPDATE 2-Teva to pay $225 mln, divest cholesterol drug to settle price-fixing charges